Containing healthcare costs and monetizing interventions by improving their return on investment
First written in FY2020. 3 of 6 entries say "Restated". Latest entry: 2026-06-24.
No other company in this theme has enough history to compare yet.
- 2026-06-24AdvancedOther Disclosures
「The following future possibilities are expected through the use of this AI model.」
The company has made concrete its plan to develop preventive healthcare by detecting people at high risk of SAS at an early stage and connecting them with detailed examinations and treatment. The goals of reducing national medical costs and monetization remain unchanged. - FY2026RestatedAnnual report
「In this business, we aim to monetize our contribution to containing Japan’s current ¥48 trillion in national healthcare expenditure by clarifying and improving the return on investment of each intervention method and encouraging appropriate investment by the government, insurers, and companies. (Source: Ministry of Health, Labour and Welfare website; fiscal 2023)」
The Company reiterated its goal of monetizing its contribution to containing national healthcare expenditure by improving the return on investment of interventions. The benchmark for national healthcare expenditure was updated from the previous ¥46 trillion to ¥48 trillion. - 2026-05-29Cited as achievedOther Disclosures
「The analysis in this white paper showed from multiple perspectives, using large-scale real-world data, that an increase of at least 1,000 average steps per day may be associated with improved health-checkup results, fewer hospitalizations for the three major diseases, and lower hospitalization costs.」
The company published analysis showing an association between increased steps and improved health-checkup results, fewer hospitalizations, and lower hospitalization costs. However, the text states that it does not directly demonstrate causality and does not indicate the return on investment or monetization of an intervention. - FY2025RestatedAnnual report
「We aim to monetize our contribution to containing Japan’s current ¥46 trillion in national healthcare expenditure by clarifying and improving the return on investment of each intervention method and encouraging appropriate investment by the government, insurers, and companies. (Source: Ministry of Health, Labour and Welfare website; fiscal 2022)」
The Company reiterated its goal of monetizing its contribution to containing national healthcare expenditure by improving the return on investment of interventions. The benchmark for national healthcare expenditure was updated from ¥44 trillion to ¥46 trillion. - FY2022RestatedAnnual report
「We aim to monetize our contribution to containing Japan’s current ¥44 trillion in national healthcare expenditure by clarifying and improving the return on investment of each intervention method and encouraging appropriate investment by the government, insurers, and companies. (Source: Ministry of Health, Labour and Welfare website; fiscal 2019)」
The Company reiterated its goal of monetizing the containment of national healthcare expenditure through measuring the effectiveness of interventions and improving their return on investment, using ¥44 trillion in national healthcare expenditure as the benchmark. - FY2020First statedAnnual report
「We aim to monetize our contribution to containing Japan’s current ¥43 trillion in national healthcare expenditure by clarifying and improving the return on investment of each intervention method and encouraging appropriate investment by the government, insurers, and companies.」
The Company set a goal of monetizing its contribution to containing national healthcare expenditure by measuring the effectiveness of health and medical interventions and improving their return on investment.